pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,973 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1837Endpoints1423Fierce Biotech743BioSpace733BioPharma Dive541raps242onclive165fda recalls
therapy area
allOncology12702Rare Disease3291Immunology2967Cardiology2833Hematology2240Pulmonology2221Vaccines
  • AI drug developer Pathos secures $237 million Series E, valuation hits $3 billion
    Pathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…
    STAT · 24d agoDealPositive↗ source
  • Few European-approved cancer drugs deliver high clinical benefit, analysis shows
    A new analysis of European regulator approvals between Jan 2022 and July 2026 finds that most newly approved cancer medicines provide limited clinical benefit. Out of 97 approved indications acros…
    STAT · 24d agoRegulatoryNegative↗ source
← prev
page 18 of 119
next →
116
fda medwatch112
globenewswire health73
fda press59
1822
Psychiatry & CNS1225
Ophthalmology1125
Endocrinology & Metabolism794
Pain784
Nephrology767
  • Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trials
    Data presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…
    STAT · 24d agoPositive readoutPositive↗ source
  • BMS reports patient death in MS CAR-T trial, cites septic pneumonia and pauses enrollment
    BMS disclosed details about a patient death that occurred in its investigational CAR-T therapy for multiple sclerosis. The autologous CD19-directed CAR-T, zolacabtagene autoleucel (zola-cel), had…
    Fierce Biotech · 24d agoNegative readoutNegative↗ source
  • Gilead agrees to pay $1.275 billion upfront for PepStar’s oral IL‑23 inhibitor, targeting J&J’s Icotyde
    Gilead Sciences has entered into a transaction to acquire PepStar Therapeutics' oral IL‑23 receptor inhibitor program. The deal is valued at $1.275 billion in upfront cash, roughly $1.3 billion as…
    Fierce Biotech · 24d agoDealPositive↗ source
  • Bolt Biotherapeutics to acquire Prana Therapies in reverse merger, secured $120M financing
    Bolt Biotherapeutics announced a stock‑for‑stock reverse merger with Prana Therapies. The transaction is supported by a $120 million financing package. The deal will bring Prana’s lead antibody in…
    Fierce Biotech · 24d agoDealPositive↗ source
  • New Medicare rules could restrict pain medication access for many patients, doctor warns
    A recent Medicare policy proposal would tighten coverage criteria for certain pain‑relief treatments, potentially limiting their availability to patients who rely on them for daily functioning. Ph…
    STAT · 24d agoRegulatoryNegative↗ source
  • Alnylam's experimental Huntington's therapy reduces mutant protein in early trial
    Alnylam Pharmaceuticals reported early data from a small study of its gene‑silencing drug for Huntington's disease. The investigational agent, brezosiran, was administered at several dose levels.…
    STAT · 24d agoPositive readoutPositive↗ source
  • Roche pays $55 million upfront to Zymeworks for global rights to trispecific antibody ZW209 targeting small-cell lung cancer
    Roche has agreed to pay Zymeworks an upfront sum of $55 million for worldwide rights to ZW209, a trispecific antibody being developed for small-cell lung cancer. ZW209 is designed to bind DLL3 on…
    Fierce Biotech · 24d agoDealNeutral↗ source
  • State officials scramble to roll out Medicaid work requirements, exchange strategies at NAMD conference
    At the National Association of Medicaid Directors (NAMD) conference, state officials gathered to discuss the rollout of Medicaid work requirements. Officials described the effort as a scramble, no…
    STAT · 24d agoRegulatoryNeutral↗ source
  • Family reflects on extra months gained from new pancreatic cancer drug daraxonrasib
    Bobby Senaha was among the first patients to receive daraxonrasib, a new medicine aimed at extending survival for people with pancreatic cancer. The drug is described as life extending, offering p…
    STAT · 24d agoPositive↗ source
  • Lung cancer patient credits targeted therapy for 15-year survival, notes limited benefit for others
    A lung cancer patient described how a targeted drug allowed her to live for 15 years after diagnosis. She highlighted that while her own quality of life improved, many of her peers who received th…
    STAT · 24d agoNeutral↗ source
  • ADA admits unclear policies after ejecting members, sparks boycott and journal shutdown
    The American Diabetes Association ejected five members from a scientific session in New Orleans on June 5 and later issued two explanations, an apology and a summary of its internal review. The org…
    STAT · 24d agoNegative↗ source
  • Callio Therapeutics appoints Chris Hassig as chief scientific officer, coming from Boundless Bio
    STAT+ regularly highlights personnel changes across the pharmaceutical sector. In its latest column the outlet reports a new senior appointment at Callio Therapeutics. The company has hired Chris…
    STAT · 24d agoPositive↗ source
  • States Challenge New Medicaid Work Requirements in Boston Court
    A federal judge in Boston heard arguments from about two dozen states contesting the Biden administration’s new Medicaid work-requirement rule. The states claim Health Secretary Robert F. Kennedy…
    STAT · 24d agoRegulatoryNegative↗ source
  • Opioid Overdose Deaths Have Plummeted, Experts Call for Deeper Investigation
    Recent data indicate a steep drop in opioid overdose deaths. The decline is notable compared with previous years. Three health experts argue that influences beyond medical treatment and public hea…
    STAT · 24d agoPositive↗ source
  • STAT honors late infectious disease reporter Helen Branswell on The Readout LOUD podcast
    The Readout LOUD podcast dedicated an episode to remembering Helen Branswell, a well‑known infectious disease journalist who passed away last week. Colleagues, family, and public health leaders sh…
    STAT · 24d agoNegative↗ source
  • Writer empathizes with Christina Applegate’s MS misdiagnosis, recalling her own 13-year diagnostic journey
    The author of the piece shares a personal connection to actress Christina Applegate’s recent revelation that she was told she no longer had multiple sclerosis, only to discover the news was a misdi…
    STAT · 24d agoNeutral↗ source
  • STAT reporters share reactions to new Elizabeth Holmes documentary
    STAT reporters attended the newly released documentary "You Can See Everything," which chronicles the rise and fall of Elizabeth Holmes and her company Theranos. The reporters offered a range of h…
    STAT · 24d agoNeutral↗ source
  • STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
    In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
    STAT · 24d ago↗ source
  • STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
    A new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.
    STAT · 24d ago↗ source
  • Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trial
    A large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…
    STAT · 25d agoPositive readoutPositive↗ source
  • Celltrion licenses Kaigene's preclinical antibody KG013 in deal worth up to $580.5 million
    Celltrion, a South Korean biotech, has entered into a licensing agreement with Maryland-based Kaigene for a preclinical monoclonal antibody known as KG013. KG013 is designed to block the prolifera…
    Fierce Biotech · 25d agoDealPositive↗ source
  • U.S. proposes rule tightening review of biotech licensing deals with Chinese firms
    The U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…
    STAT · 25d agoRegulatoryNeutral↗ source
  • Menarini's Stemline signs $1.1 billion deal to license Georgiamune's preclinical cancer immunotherapy
    Georgiamune, a Maryland‑based immunology biotech, has granted Stemline Therapeutics, part of Italy's Menarini Group, exclusive worldwide rights to develop and commercialize its preclinical cancer c…
    Fierce Biotech · 25d agoDealPositive↗ source